Evidence map›Paper›PMID 32368520›Full record

ArticlePublic health action2020

Pre-treatment lost to follow-up tuberculosis patients, Chongwe, Zambia, 2017: a retrospective cohort study.

M Chilembo, S Oguri, Y Matsuoka, M Ota, P Musiankuni, J Kabungo

Open access · diamondAbstract read
In one paragraph

Article in Public health action, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

M ChilemboJapan Anti-Tuberculosis Association, Lusaka, Zambia.
S OguriJapan Anti-Tuberculosis Association, Lusaka, Zambia.
Y MatsuokaJapan Anti-Tuberculosis Association, Lusaka, Zambia.
M OtaResearch Institute of Tuberculosis, Tokyo, Japan.
P MusiankuniChongwe District Health Office, Ministry of Health, Chongwe, Zambia.
J KabungoChongwe District Health Office, Ministry of Health, Chongwe, Zambia.
Japan Anti Tuberculosis Association · JPMinistry of Health · ZM

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

settingFour tuberculosis (TB) diagnostic health facilities of the Chongwe District, Zambia.

objectiveTo determine the frequency of bacteriologically confirmed TB patients lost to follow-up (LTFU) before treatment from January to December 2017.

designThis is a retrospective cohort study involving the review of TB registers. Information on presumptive TB patients who tested positive either by smear microscopy or Xpert

resultsTwo hundred and seventeen bacteriologically confirmed TB patients were found in the laboratory TB registers. Of these, 145 (67%) were males and seven (3%) were children; 177 (81%) patients were diagnosed using Xpert, while the remaining 40 (19%) were diagnosed using sputum smear microscopy. A total of 71 (33%) were not linked to treatment. Those diagnosed using smear microscopy were 2.5 times (95% CI 1.1-5.3) more likely to be LTFU before treatment than those diagnosed using Xpert.

conclusionAbout one third of TB patients who were not linked to treatment could potentially extend the duration of bacilli transmission in their communities. National TB control programmes should consider including LTFU patients before treatment in routine monitoring and evaluation.

Indexed as

epidemiologypre-treatment lost to follow-upTBtreatmentZambia

Identifiers

PMID32368520
PMCPMC7181362
OpenAlexW3019809375

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.